{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T08:23:05Z","timestamp":1763194985951,"version":"3.45.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82170205"],"award-info":[{"award-number":["82170205"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06694-3","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T06:40:20Z","timestamp":1761288020000},"page":"5359-5369","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Developmental stage modulates the prognostic impact of RAS pathway mutations in AML patients undergoing Allo-HSCT"],"prefix":"10.1007","volume":"104","author":[{"given":"Xiaolin","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yibo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panpan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luxin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanmin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingsong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"issue":"23","key":"6694_CR1","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374(23):2209\u20132221. https:\/\/doi.org\/10.1056\/NEJMoa1516192","journal-title":"N Engl J Med"},{"issue":"22","key":"6694_CR2","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"J Timothy","year":"2013","unstructured":"Cancer Genome Atlas Research Network, Timothy J, Ley C, Miller L, Ding BJ, Raphael AJ, Mungall et al (2013) Genomic and epigenomic landscapes of adult de Novo acute myeloid leukemia. N Engl J Med 368(22):2059\u20132074. https:\/\/doi.org\/10.1056\/NEJMoa1301689","journal-title":"N Engl J Med"},{"issue":"6","key":"6694_CR3","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1182\/blood-2008-01-134262","volume":"113","author":"J Zhang","year":"2009","unstructured":"Zhang J, Wang J, Liu Y, Sidik H, Young KH, Lodish HF et al (2009) Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. Blood 113(6):1304\u20131314. https:\/\/doi.org\/10.1182\/blood-2008-01-134262","journal-title":"Blood"},{"issue":"7","key":"6694_CR4","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1182\/blood-2004-08-009498","volume":"108","author":"C Parikh","year":"2006","unstructured":"Parikh C, Subrahmanyam R, Ren R (2006) Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice. Blood 108(7):2349\u20132357. https:\/\/doi.org\/10.1182\/blood-2004-08-009498","journal-title":"Blood"},{"issue":"1","key":"6694_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H et al (2022) Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther 7(1):51. https:\/\/doi.org\/10.1038\/s41392-021-00870-3","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"6694_CR6","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1158\/2159-8290.Cd-18-1453","volume":"9","author":"CM McMahon","year":"2019","unstructured":"McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ et al (2019) Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 Inhibition in acute myeloid leukemia. Cancer Discov 9(8):1050\u20131063. https:\/\/doi.org\/10.1158\/2159-8290.Cd-18-1453","journal-title":"Cancer Discov"},{"key":"6694_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2018.03.001","volume":"54","author":"AQ Khan","year":"2019","unstructured":"Khan AQ, Kuttikrishnan S, Siveen KS, Prabhu KS, Shanmugakonar M, Al-Naemi HA et al (2019) RAS-mediated oncogenic signaling pathways in human malignancies. Semin Cancer Biol 54:1\u201313. https:\/\/doi.org\/10.1016\/j.semcancer.2018.03.001","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"6694_CR8","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3324\/haematol.2020.269431","volume":"107","author":"T Kaburagi","year":"2022","unstructured":"Kaburagi T, Yamato G, Shiba N, Yoshida K, Hara Y, Tabuchi K et al (2022) Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia. Haematologica 107(3):583\u2013592. https:\/\/doi.org\/10.3324\/haematol.2020.269431","journal-title":"Haematologica"},{"issue":"7728","key":"6694_CR9","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL et al (2018) Functional genomic landscape of acute myeloid leukaemia. Nature 562(7728):526\u2013531. https:\/\/doi.org\/10.1038\/s41586-018-0623-z","journal-title":"Nature"},{"issue":"22","key":"6694_CR10","doi-asserted-by":"publisher","first-page":"5550","DOI":"10.1002\/cncr.27596","volume":"118","author":"TM Kadia","year":"2012","unstructured":"Kadia TM, Kantarjian H, Kornblau S, Borthakur G, Faderl S, Freireich EJ et al (2012) Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer 118(22):5550\u20135559. https:\/\/doi.org\/10.1002\/cncr.27596","journal-title":"Cancer"},{"issue":"6","key":"6694_CR11","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1182\/blood-2005-03-0867","volume":"106","author":"DT Bowen","year":"2005","unstructured":"Bowen DT, Frew ME, Hills R, Gale RE, Wheatley K, Groves MJ et al (2005) RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood 106(6):2113\u20132119. https:\/\/doi.org\/10.1182\/blood-2005-03-0867","journal-title":"Blood"},{"issue":"12","key":"6694_CR12","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/ajh.26731","volume":"97","author":"D Rivera","year":"2022","unstructured":"Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver N et al (2022) Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol 97(12):1599\u20131606. https:\/\/doi.org\/10.1002\/ajh.26731","journal-title":"Am J Hematol"},{"issue":"12","key":"6694_CR13","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1038\/s41375-018-0147-4","volume":"32","author":"A-K Eisfeld","year":"2018","unstructured":"Eisfeld A-K, Kohlschmidt J, Mr\u00f3zek K, Mims A, Walker CJ, Blachly JS et al (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32(12):2536\u20132545. https:\/\/doi.org\/10.1038\/s41375-018-0147-4","journal-title":"Leukemia"},{"issue":"3","key":"6694_CR14","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41375-020-0920-z","volume":"35","author":"M Alfayez","year":"2020","unstructured":"Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ et al (2020) The clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia 35(3):691\u2013700. https:\/\/doi.org\/10.1038\/s41375-020-0920-z","journal-title":"Leukemia"},{"issue":"8","key":"6694_CR15","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K et al (2022) Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell 40(8):850\u2013864e859. https:\/\/doi.org\/10.1016\/j.ccell.2022.07.002","journal-title":"Cancer Cell"},{"issue":"10","key":"6694_CR16","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/2159-8290.CD-19-1469","volume":"10","author":"SF Cai","year":"2023","unstructured":"Cai SF, Chu SH, Goldberg AD, Parvin S, Koche RP, Glass JL et al (2023) Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 Inhibition. Cancer Discov 10(10):1500\u20131513. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1469","journal-title":"Cancer Discov"},{"issue":"9","key":"6694_CR17","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297\/3342626\/cd-22-1297.pdf","volume":"13","author":"IT Shanshan Pei","year":"2023","unstructured":"Shanshan Pei IT, Shelton AE, Gillen BM, Stevens M, Gasparetto Y, Wang et al (2023) A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. Cancer Discov 13(9):2032\u20132049. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1297\/3342626\/cd-22-1297.pdf","journal-title":"Cancer Discov"},{"issue":"1","key":"6694_CR18","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1038\/s41467-021-22874-x","volume":"12","author":"F Wang","year":"2021","unstructured":"Wang F, Morita K, DiNardo CD, Furudate K, Tanaka T, Yan Y et al (2021) Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun 12(1):2607. https:\/\/doi.org\/10.1038\/s41467-021-22874-x","journal-title":"Nat Commun"},{"issue":"12","key":"6694_CR19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"AH Hartmut D\u00f6hner","year":"2022","unstructured":"Hartmut D\u00f6hner AH, Wei FR, Appelbaum C, Craddock, Courtney D, DiNardo et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"issue":"4","key":"6694_CR20","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R et al (2020) Monocytic subclones confer resistance to Venetoclax-Based therapy in patients with acute myeloid leukemia. Cancer Discov 10(4):536\u2013551. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0710","journal-title":"Cancer Discov"},{"issue":"4","key":"6694_CR21","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","volume":"33","author":"JM Bennett","year":"1976","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33(4):451\u2013458","journal-title":"Br J Haematol"},{"issue":"1","key":"6694_CR22","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1038\/s41467-024-45916-6","volume":"15","author":"B Wang","year":"2024","unstructured":"Wang B, Reville PK, Yassouf MY, Jelloul FZ, Ly C, Desai PN et al (2024) Comprehensive characterization of IFNgamma signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies. Nat Commun 15(1):1821. https:\/\/doi.org\/10.1038\/s41467-024-45916-6","journal-title":"Nat Commun"},{"issue":"26","key":"6694_CR23","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL et al (2021) Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 138(26):2753\u20132767. https:\/\/doi.org\/10.1182\/blood.2021013626","journal-title":"Blood"},{"issue":"17","key":"6694_CR24","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1182\/blood-2014-04-571570","volume":"124","author":"Y Luo","year":"2014","unstructured":"Luo Y, Xiao H, Lai X, Shi J, Tan Y, He J et al (2014) T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte Globulin compared with matched sibling HSCT and unrelated HSCT. Blood 124(17):2735\u20132743. https:\/\/doi.org\/10.1182\/blood-2014-04-571570","journal-title":"Blood"},{"issue":"17","key":"6694_CR25","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1182\/bloodadvances.2021004631","volume":"5","author":"S Stasik","year":"2021","unstructured":"Stasik S, Eckardt JN, Kramer M, Rollig C, Kramer A, Scholl S et al (2021) Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. Blood Adv 5(17):3279\u20133289. https:\/\/doi.org\/10.1182\/bloodadvances.2021004631","journal-title":"Blood Adv"},{"issue":"14","key":"6694_CR26","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1182\/blood-2017-07-798157","volume":"131","author":"N Murakami","year":"2018","unstructured":"Murakami N, Okuno Y, Yoshida K, Shiraishi Y, Nagae G, Suzuki K et al (2018) Integrated molecular profiling of juvenile myelomonocytic leukemia. Blood 131(14):1576\u20131586. https:\/\/doi.org\/10.1182\/blood-2017-07-798157","journal-title":"Blood"},{"issue":"11","key":"6694_CR27","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/ng.3420","volume":"47","author":"A Caye","year":"2015","unstructured":"Caye A, Strullu M, Guidez F, Cassinat B, Gazal S, Fenneteau O et al (2015) Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Nat Genet 47(11):1334\u20131340. https:\/\/doi.org\/10.1038\/ng.3420","journal-title":"Nat Genet"},{"issue":"3","key":"6694_CR28","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41375-019-0603-9","volume":"34","author":"FPS Santos","year":"2020","unstructured":"Santos FPS, Getta B, Masarova L, Famulare C, Schulman J, Datoguia TS et al (2020) Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. Leukemia 34(3):799\u2013810. https:\/\/doi.org\/10.1038\/s41375-019-0603-9","journal-title":"Leukemia"},{"issue":"7","key":"6694_CR29","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and Histiocytic\/Dendritic neoplasms. Leukemia 36(7):1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"issue":"1","key":"6694_CR30","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1186\/s12967-023-04579-5","volume":"21","author":"X Wu","year":"2023","unstructured":"Wu X, Wu Z, Deng W, Xu R, Ban C, Sun X et al (2023) Spatiotemporal evolution of AML immune microenvironment remodeling and RNF149-driven drug resistance through single-cell multidimensional analysis. J Transl Med 21(1):760. https:\/\/doi.org\/10.1186\/s12967-023-04579-5","journal-title":"J Transl Med"},{"issue":"1","key":"6694_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","volume":"36","author":"S Tettamanti","year":"2022","unstructured":"Tettamanti S, Pievani A, Biondi A, Dotti G, Serafini M (2022) Catch me if you can: how AML and its niche escape immunotherapy. Leukemia 36(1):13\u201322. https:\/\/doi.org\/10.1038\/s41375-021-01350-x","journal-title":"Leukemia"},{"issue":"6","key":"6694_CR32","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/s41375-024-02217-7","volume":"38","author":"A Perzolli","year":"2024","unstructured":"Perzolli A, Koedijk JB, Zwaan CM, Heidenreich O (2024) Targeting the innate immune system in pediatric and adult AML. Leukemia 38(6):1191\u20131201. https:\/\/doi.org\/10.1038\/s41375-024-02217-7","journal-title":"Leukemia"},{"issue":"1","key":"6694_CR33","doi-asserted-by":"publisher","first-page":"12152","DOI":"10.1038\/s41598-020-69194-6","volume":"10","author":"S Wang","year":"2020","unstructured":"Wang S, Wu Z, Li T, Li Y, Wang W, Hao Q et al (2020) Mutational spectrum and prognosis in NRAS-mutated acute myeloid leukemia. Sci Rep 10(1):12152. https:\/\/doi.org\/10.1038\/s41598-020-69194-6","journal-title":"Sci Rep"},{"issue":"6","key":"6694_CR34","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen P, Hovestadt V, Wadsworth Ii MH, Hughes TK, Griffin GK, Battaglia S et al (2019) Single-Cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity. Cell 176(6):1265\u20131281e1224. https:\/\/doi.org\/10.1016\/j.cell.2019.01.031","journal-title":"Cell"},{"issue":"1","key":"6694_CR35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41409-023-02137-7","volume":"59","author":"L Yang","year":"2024","unstructured":"Yang L, Lai X, Yang T, Lu Y, Liu L, Shi J et al (2024) Prophylactic versus preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study. Bone Marrow Transpl 59(1):85\u201392. https:\/\/doi.org\/10.1038\/s41409-023-02137-7","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"6694_CR36","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00277-020-04326-6","volume":"100","author":"XL Yuan","year":"2020","unstructured":"Yuan XL, Tan YM, Shi JM, Zhao YM, Yu J, Lai XY et al (2020) Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Ann Hematol 100(2):517\u2013527. https:\/\/doi.org\/10.1007\/s00277-020-04326-6","journal-title":"Ann Hematol"},{"issue":"3","key":"6694_CR37","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41409-020-01088-7","volume":"56","author":"L Yang","year":"2020","unstructured":"Yang L, Tan Y, Shi J, Zhao Y, Yu J, Hu Y et al (2020) Prophylactic modified donor lymphocyte infusion after low-dose ATG-F-based haploidentical HSCT with myeloablative conditioning in high-risk acute leukemia: a matched-pair analysis. Bone Marrow Transpl 56(3):664\u2013672. https:\/\/doi.org\/10.1038\/s41409-020-01088-7","journal-title":"Bone Marrow Transpl"},{"key":"6694_CR38","doi-asserted-by":"publisher","first-page":"217264","DOI":"10.1016\/j.canlet.2024.217264","volume":"605","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chang YJ, Chen J, Han M, Hu J, Hu J et al (2024) Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic Haematopoietic stem cell transplantation in china: 2024 update. Cancer Lett 605:217264. https:\/\/doi.org\/10.1016\/j.canlet.2024.217264","journal-title":"Cancer Lett"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06694-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06694-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06694-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T08:19:07Z","timestamp":1763194747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06694-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6694"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06694-3","relation":{},"ISSN":["1432-0584"],"issn-type":[{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"27 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Review Committee of the First Affiliated Hospital, Zhejiang University School of Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest\u00a0<!--Emphasis Type='Bold' removed-->statement"}}]}}